Literature DB >> 1747567

Long-term anabolic effects of prostaglandin-E2 on tibial diaphyseal bone in male rats.

W S Jee1, H Z Ke, X J Li.   

Abstract

The effects of long-term prostaglandin E2 (PGE2) on tibial diaphyseal bone were studied in 7-month-old male Sprague-Dawley rats given daily subcutaneous injections of 0, 1, 3 and 6 mg PGE2/kg/day for 60, 120 and 180 days. The tibial shaft was measured by single photon absorptiometry and dynamic histomorphometric analyses were performed on double-fluorescent labeled undecalcified tibial diaphyseal bone samples. Exogenous PGE2 administration produced the following transient changes in a dose-response manner between zero and 60 days: 1) increased bone width and mineral density; 2) increased total tissue and total bone areas; 3) decreased marrow area; 4) increased periosteal and corticoendosteal lamellar bone formation; 5) activated corticoendosteal lamellar and woven trabecular bone formation and 6) activated intracortical bone remodeling. A new steady-state of increased tibial diaphyseal bone mass and elevated bone activities were observed from day 60 onward. The elevated bone mass level attained after 60 days of PGE2 treatment was maintained at 120 and 180 days. These observations indicate that the powerful anabolic effects of PGE2 will increase both periosteal and corticoendosteal bone mass and sustain the transient increase in bone mass with continuous daily administration of PGE2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747567     DOI: 10.1016/0169-6009(91)90109-d

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  12 in total

1.  Alteration of femoral bone morphology and density in COX-2-/- mice.

Authors:  Galen Robertson; Chao Xie; Di Chen; Hani Awad; Edward M Schwarz; Regis J O'Keefe; Robert E Guldberg; Xinping Zhang
Journal:  Bone       Date:  2006-05-30       Impact factor: 4.398

2.  Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice.

Authors:  Kiminori Yukata; Chao Xie; Tian-Fang Li; Matthew L Brown; Tsukasa Kanchiku; Xinping Zhang; Hani A Awad; Edward M Schwarz; Christopher A Beck; Jennifer H Jonason; Regis J O'Keefe
Journal:  Bone       Date:  2018-02-03       Impact factor: 4.398

3.  Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.

Authors:  Zachary C Ryan; Theodore A Craig; Jeffrey L Salisbury; Lomeli R Carpio; Meghan McGee-Lawrence; Jennifer J Westendorf; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2014-04-26       Impact factor: 3.575

4.  Effects of cyclic hydraulic pressure on osteocytes.

Authors:  Chao Liu; Yan Zhao; Wing-Yee Cheung; Ronak Gandhi; Liyun Wang; Lidan You
Journal:  Bone       Date:  2010-02-10       Impact factor: 4.398

Review 5.  Perspectives on osteoporosis research: its focus and some insights from a new paradigm.

Authors:  J L Ferretti; H M Frost; J A Gasser; W B High; W S Jee; C Jerome; L Mosekilde; D D Thompson
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

6.  Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the rat.

Authors:  G N Mann; D A Sass; H K Chen; F J Buchinsky; H P Bryer; Y F Ma; W S Jee; B Rucinski; S Epstein
Journal:  Calcif Tissue Int       Date:  1996-07       Impact factor: 4.333

7.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4.

Authors:  Chao Xie; Bojian Liang; Ming Xue; Angela S P Lin; Alayna Loiselle; Edward M Schwarz; Robert E Guldberg; Regis J O'Keefe; Xinping Zhang
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

8.  Increased bone growth by local prostaglandin E2 in rats.

Authors:  R S Yang; T K Liu; S Y Lin-Shiau
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

9.  Osteotropic beta-cyclodextrin for local bone regeneration.

Authors:  Xin-Ming Liu; Andrew T Wiswall; John E Rutledge; Mohammed P Akhter; Diane M Cullen; Richard A Reinhardt; Dong Wang
Journal:  Biomaterials       Date:  2008-01-15       Impact factor: 12.479

10.  In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells.

Authors:  Benjamin J Frisch; Rebecca L Porter; Benjamin J Gigliotti; Adam J Olm-Shipman; Jonathan M Weber; Regis J O'Keefe; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2009-09-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.